DR5, Blocking Peptide DR5 (Apo2, Trail-R2, TRAIL Receptor2, Trick2, Killer, Death Receptor5), Purifi

Peptide corresponding to amino acids 388 to 407 of human DR5 precursor (1,2). Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently (1-7). Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kB. Human sTRAIL Receptor-2 is a 14.9kD protein containing 133 amino acid residues comprising the extracellular domain of TRAIL Receptor-2. , Applications:, Suitable for use in ELISA and Antibody Blocking. Other applications not tested. Recommended Dilution: Incubation of peptide with equal volume of antibody for 30 minutes at 37°C completely blocks the antibody activity in Westen Blot. Storage and Stability: For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.